HK1211306A1 - Methods for identifying antibodies with reduced immunogenicity - Google Patents

Methods for identifying antibodies with reduced immunogenicity

Info

Publication number: HK1211306A1
Authority: HK; Hong Kong
Prior art keywords: methods; reduced immunogenicity; identifying antibodies; antibodies; identifying
Prior art date: 2012-09-19

Application number

HK15112156.8A

Other languages

English (en)

Chinese (zh)

Inventor

Fiona A Harding

Olivia Jennifer Razo

Original Assignee

Abbvie Biotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-19

Filing date

2015-12-09

Publication date

2016-05-20

2015-12-09 Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc

2016-05-20 Publication of HK1211306A1 publication Critical patent/HK1211306A1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Pathology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

HK15112156.8A 2012-09-19 2015-12-09 Methods for identifying antibodies with reduced immunogenicity HK1211306A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261703170P	2012-09-19	2012-09-19
PCT/US2013/060480 WO2014047222A2 (en)	2012-09-19	2013-09-18	Methods for identifying antibodies with reduced immunogenicity

Publications (1)

Publication Number	Publication Date
HK1211306A1 true HK1211306A1 (en)	2016-05-20

Family

ID=49304336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15112156.8A HK1211306A1 (en)	2012-09-19	2015-12-09	Methods for identifying antibodies with reduced immunogenicity

Country Status (27)

Country	Link
US (1)	US9279016B2 (es)
EP (2)	EP2897978B1 (es)
JP (1)	JP2015537190A (es)
KR (1)	KR20150056788A (es)
CN (1)	CN104704000A (es)
AU (1)	AU2013318147B2 (es)
BR (1)	BR112015005857A2 (es)
CA (1)	CA2885422A1 (es)
CY (1)	CY1118893T1 (es)
DK (1)	DK2897978T3 (es)
ES (1)	ES2621285T3 (es)
HK (1)	HK1211306A1 (es)
HR (1)	HRP20170937T1 (es)
HU (1)	HUE032569T2 (es)
IL (1)	IL237833A0 (es)
IN (1)	IN2015DN01967A (es)
LT (1)	LT2897978T (es)
MX (1)	MX2015003541A (es)
NZ (1)	NZ705606A (es)
PL (1)	PL2897978T3 (es)
PT (1)	PT2897978T (es)
RS (1)	RS56093B1 (es)
RU (1)	RU2648141C2 (es)
SG (1)	SG11201502094TA (es)
SI (1)	SI2897978T1 (es)
TW (1)	TWI519646B (es)
WO (1)	WO2014047222A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106478802B (zh) *	2016-10-11	2019-08-09	浙江省人民医院	TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
CN110382696B (zh) *	2017-03-07	2024-04-19	豪夫迈·罗氏有限公司	发现替代性抗原特异性抗体变体的方法
WO2020128863A1 (en) *	2018-12-19	2020-06-25	Novartis Ag	Anti-tnf-alpha antibodies
EP3997124A4 (en) *	2019-07-09	2024-01-03	Nat Institute For Biotechnology In The Negev Ltd	ANTIBODIES WITH REDUCED IMMUNOGENICITY
JP2022550390A (ja)	2019-09-30	2022-12-01	スキロムゲゼルシャフトミットベシュレンクテルハフツング	ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー
FR3104582A1 (fr) *	2019-12-17	2021-06-18	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) *	2019-12-31	2023-06-16	科美博阳诊断技术(上海)有限公司	一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) *	2020-01-20	2021-07-29	Bio-Thera Solutions, Ltd.	Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) *	2020-11-16	2023-08-24	바디텍메드(주)	항 약물 항체의 신속 검출 방법
BR112023017035A2 (pt)	2021-03-01	2024-02-06	New York Soc For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surger	Anticorpos humanizados contra irhom2, ácido nucleico, uso do anticorpo, composição farmacêutica, composição, método de tratamento e kit terapêutico
US20240174744A1 (en)	2021-03-29	2024-05-30	Scirhom Gmbh	Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en)	2021-04-09	2022-10-13	Philogen S.P.A.	Improved interferon-gamma mutant
WO2024023246A1 (en)	2022-07-28	2024-02-01	Philogen S.P.A.	Antibody binding to pd1
WO2024033362A1 (en)	2022-08-08	2024-02-15	Atb Therapeutics	Humanized antibodies against cd79b

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
DE3687170T2 (de)	1985-01-25	1993-04-01	Kitasato Inst	Antitumorale antibiotika und deren herstellung.
US5264357A (en)	1985-05-24	1993-11-23	Genentech, Inc.	Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en)	1991-07-17	1993-11-23	The Scripps Research Institute	Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
BRPI9715219B8 (pt) *	1996-02-09	2015-07-07	Abbvie Biotechnology Ltd	Vetor recombinante de expressão, e célula hospedeira procariótica.
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en)	1998-07-30	2004-09-07	Solexa Ltd.	Arrayed biomolecules and their use in sequencing
AR021833A1 (es)	1998-09-30	2002-08-07	Applied Research Systems	Metodos de amplificacion y secuenciacion de acido nucleico
JP2002530081A (ja)	1998-11-18	2002-09-17	ジェネンテック・インコーポレーテッド	親抗体より高度な結合親和性を持つ抗体変異体
US7211390B2 (en)	1999-09-16	2007-05-01	454 Life Sciences Corporation	Method of sequencing a nucleic acid
WO2001023610A2 (en)	1999-09-29	2001-04-05	Solexa Ltd.	Polynucleotide sequencing
US6686168B1 (en)	1999-11-04	2004-02-03	Zymogenetics, Inc.	Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) *	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2001293163A1 (en)	2000-09-27	2002-04-08	Lynx Therapeutics, Inc.	Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en)	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US6956114B2 (en)	2001-10-30	2005-10-18	'454 Corporation	Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en)	2001-12-04	2006-06-06	Solexa Limited	Labelled nucleotides
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
AU2003283995A1 (en)	2002-09-30	2004-04-19	Protein Design Labs, Inc.	Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
DK1725249T3 (en)	2003-11-06	2014-03-17	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugating to ligands.
WO2005123780A2 (en)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TW201705980A (zh) *	2004-04-09	2017-02-16	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
JP2009515878A (ja)	2005-11-12	2009-04-16	イーライリリーアンドカンパニー	抗ｅｇｆｒ抗体
JP5759722B2 (ja) *	2007-08-28	2015-08-05	アッヴィバイオテクノロジーリミテッド	アダリムマブの結合蛋白質を含む組成物及び方法
WO2009059235A2 (en)	2007-11-01	2009-05-07	Facet Biotech Corporation	Immunoglobulin display vectors
EP2918602A1 (en) *	2009-04-16	2015-09-16	AbbVie Biotherapeutics Inc.	Anti-TNF-alpha antibodies and their uses
GB0909904D0 (en) *	2009-06-09	2009-07-22	Affitech As	Product
BR112012022917A2 (pt) *	2010-03-11	2017-01-10	Pfizer	anticorpos com ligação a antígeno dependente de ph
CA2806640A1 (en) *	2010-08-13	2012-02-16	Roche Glycart Ag	Anti-tenascin-c a2 antibodies and methods of use
AU2011318574B2 (en) *	2010-10-20	2016-03-03	Oxford Biotherapeutics Ltd.	Antibodies

2013
- 2013-09-18 RS RS20170609A patent/RS56093B1/sr unknown
- 2013-09-18 TW TW102134040A patent/TWI519646B/zh not_active IP Right Cessation
- 2013-09-18 WO PCT/US2013/060480 patent/WO2014047222A2/en active Application Filing
- 2013-09-18 BR BR112015005857A patent/BR112015005857A2/pt active Search and Examination
- 2013-09-18 PT PT137734745T patent/PT2897978T/pt unknown
- 2013-09-18 NZ NZ705606A patent/NZ705606A/en not_active IP Right Cessation
- 2013-09-18 SG SG11201502094TA patent/SG11201502094TA/en unknown
- 2013-09-18 EP EP13773474.5A patent/EP2897978B1/en active Active
- 2013-09-18 JP JP2015533163A patent/JP2015537190A/ja active Pending
- 2013-09-18 CA CA2885422A patent/CA2885422A1/en not_active Abandoned
- 2013-09-18 DK DK13773474.5T patent/DK2897978T3/en active
- 2013-09-18 AU AU2013318147A patent/AU2013318147B2/en not_active Ceased
- 2013-09-18 CN CN201380048863.XA patent/CN104704000A/zh active Pending
- 2013-09-18 EP EP17154662.5A patent/EP3211006A3/en not_active Withdrawn
- 2013-09-18 HU HUE13773474A patent/HUE032569T2/en unknown
- 2013-09-18 SI SI201330608A patent/SI2897978T1/sl unknown
- 2013-09-18 MX MX2015003541A patent/MX2015003541A/es unknown
- 2013-09-18 US US14/030,977 patent/US9279016B2/en not_active Expired - Fee Related
- 2013-09-18 LT LTEP13773474.5T patent/LT2897978T/lt unknown
- 2013-09-18 ES ES13773474.5T patent/ES2621285T3/es active Active
- 2013-09-18 IN IN1967DEN2015 patent/IN2015DN01967A/en unknown
- 2013-09-18 KR KR1020157007286A patent/KR20150056788A/ko not_active Application Discontinuation
- 2013-09-18 PL PL13773474T patent/PL2897978T3/pl unknown
- 2013-09-18 RU RU2015111671A patent/RU2648141C2/ru not_active IP Right Cessation
2015
- 2015-03-19 IL IL237833A patent/IL237833A0/en unknown
- 2015-12-09 HK HK15112156.8A patent/HK1211306A1/xx not_active IP Right Cessation
2017
- 2017-04-11 CY CY20171100428T patent/CY1118893T1/el unknown
- 2017-06-20 HR HRP20170937TT patent/HRP20170937T1/hr unknown

Also Published As

Publication number	Publication date
DK2897978T3 (en)	2017-05-15
WO2014047222A3 (en)	2014-10-23
WO2014047222A2 (en)	2014-03-27
AU2013318147A1 (en)	2015-03-19
TW201418469A (zh)	2014-05-16
MX2015003541A (es)	2015-10-26
HUE032569T2 (en)	2017-09-28
SG11201502094TA (en)	2015-04-29
SI2897978T1 (sl)	2017-05-31
IL237833A0 (en)	2015-05-31
PT2897978T (pt)	2017-05-22
RS56093B1 (sr)	2017-10-31
CY1118893T1 (el)	2018-01-10
PL2897978T3 (pl)	2017-08-31
KR20150056788A (ko)	2015-05-27
WO2014047222A9 (en)	2014-06-26
EP2897978B1 (en)	2017-03-22
AU2013318147B2 (en)	2018-01-04
RU2015111671A (ru)	2016-11-10
LT2897978T (lt)	2017-06-12
ES2621285T3 (es)	2017-07-03
CA2885422A1 (en)	2014-03-27
HRP20170937T1 (hr)	2017-11-03
EP3211006A3 (en)	2017-11-08
EP3211006A2 (en)	2017-08-30
RU2648141C2 (ru)	2018-03-22
TWI519646B (zh)	2016-02-01
IN2015DN01967A (es)	2015-08-14
NZ705606A (en)	2018-05-25
US9279016B2 (en)	2016-03-08
CN104704000A (zh)	2015-06-10
BR112015005857A2 (pt)	2017-08-08
US20140227251A1 (en)	2014-08-14
JP2015537190A (ja)	2015-12-24
EP2897978A2 (en)	2015-07-29

Legal Events

Date	Code	Title	Description
2022-04-14	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20210920

Publication	Publication Date	Title
IL264558A (en)	2019-02-28	Anti–il–23p19 antibodies
HRP20170937T1 (hr)	2017-11-03	Postupci za identifikaciju antitijela smanjene imunogenosti
ZA201407509B (en)	2016-02-24	Anti-fcrn antibodies
HK1204571A1 (en)	2015-11-27	Protease-regulated antibodies
HK1203517A1 (en)	2015-10-30	Multispecific antibodies
HK1210192A1 (en)	2016-04-15	Anti-siglec-15 antibodies siglec-15
EP2930240A4 (en)	2016-07-13	ANTI-FOLR1 ANTIBODY
EP2844290A4 (en)	2015-12-16	NOVEL ANTIBODIES
EP2837685A4 (en)	2016-02-24	ANTI-FGFR2 ANTIBODIES
HK1210186A1 (en)	2016-04-15	Anti-h7cr antibodies h7cr
PL2935330T3 (pl)	2019-11-29	Przeciwciała przeciw notch3
EP2804876A4 (en)	2016-02-24	NEW ANTIBODIES
EP2931743A4 (en)	2016-08-03	METHOD FOR ASSESSING IMMUNOGENICITY
EP2848633A4 (en)	2015-12-30	ANTI-CXADR ANTIBODY
EP2811018A4 (en)	2015-05-13	ANTI-BODY ANTI-sAPPß
IL235188A0 (en)	2014-12-31	Antibodies against c-pdgf
GB201209584D0 (en)	2012-07-11	Modified antibodies
GB201216749D0 (en)	2012-10-31	Antigen combinations
GB201200568D0 (en)	2012-02-29	Antigen combinations